Amarin Corp Plc (AMRN)

[Laurent Maldague]

Thanks a lot for sharing and that's an amazing personal result. Seems to me like V is quite efficacious at lowering Lp-PLA2.

Pulled out the Lp-PLA2 table from the latest article for your convenience. Seems like Reduce-IT baseline Lp-PLA2 levels were even lower than Anchor. Interesting that the EPA group numbers were at first slightly decreasing, but then rose back to baseline at the end of the study, which seems to suggest Lp-PLA2 was worsening overall? Curious what you think of the trend.


And if you want more oddities, both interleukin-6 and lipoprotein(a) actually went up from baseline in the EPA arm (statistically significant). It's seems difficult to really make anything from this biomarker analysis. Hs-CRP in the EPA arm was significantly reduced at 12 and 24 months, but lost significance by trial end. It seems to me one could make the argument that the biomarkers were worsening overall (disease progression hypothesis).


all snippets pulled from https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059410